Scientists at the QIMR Berghofer Medical Research Institute have achieved a groundbreaking advancement in creating the first-ever vaccine against the Epstein-Barr virus (EBV), responsible for infectious mononucleosis and linked to cancer and multiple sclerosis. The vaccine stimulates antibodies and T cells, integral components of the immune system, to combat EBV. It also offers a unique defense against EBV-associated tumors, potentially preventing secondary conditions like brain inflammation and multiple sclerosis. The team aims to begin human clinical trials, expected to start around 2024 or 2025, with initial funding secured from industry partners. This milestone holds promise for addressing EBV-related health concerns.